AstraZeneca to present data from four Phase III trials at ESMO 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. S
10. COF

Go back to AstraZeneca to present data from four Phase III trials at ESMO 2026

AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitini

October 19, 2026 7:00 AM EDT

CLARITY-Gastric01 data will demonstrate potential of Sone-Ve to establish new treatment for broad population of CLDN18.2-positive gastric cancer patients

SAFFRON results will highlight clinical benefit of adding savolitinib to backbone TAGRISSO in MET-driven 2nd-line EGFRm lung cancer

VOLGA and DeLLphi-305 data will showcase the transformative potential of combining IMFINZI with novel agents to set new standards of care in bladder and small cell lung cancer

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca advances its ambition to revolutionize cancer care with new data across its... More